Brief: Nanoviricides Says Progressing Toward Clinical Trials for Herpecide Drug Candidate
20/05/2019 12:44
May 20 (Reuters) - NanoViricides Inc NNVC.A :
* NANOVIRICIDES INC - HERPECIDE DRUG CANDIDATE PRE-IND
APPLICATION
SUBMITTED, PROGRESSING TOWARDS CLINICAL TRIALS
* NANOVIRICIDES INC - HAD APPROXIMATELY $4.63 MILLION OF
CURRENT
ASSETS AND CURRENT CASH LIABILITIES OF APPROXIMATELY $1.08M, AS
OF MARCH 31, 2019
Source text for Eikon: ID:nPn6Kv05na
Further company coverage: NNVC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments